Dublin, Nov. 30, 2023 (GLOBE NEWSWIRE) -- The "Global Antibody Contract Manufacturing Market 2023" report has been added to ResearchAndMarkets.com's offering.
The global antibody contract manufacturing market is expected to grow from $11.18 billion in 2022 to $12.84 billion in 2023 at a compound annual growth rate (CAGR) of 14.82%. The antibody contract manufacturing market is expected to reach $21.79 billion in 2027 at a CAGR of 14.13%. 
The rising number of clinical trials is expected to propel the growth of the antibody contract manufacturing market going forward. The number of clinical trials involving antibody-based therapeutics or diagnostics expands, for high-quality antibodies, ensuring a timely and compliant supply for clinical trials. For instance, in May 2023, according to ClinicalTrials.gov, a part of the National Institutes of Health (NIH), a US-based government agency responsible for conducting and supporting medical research, in all 50 states of the United States and 221 countries, the number of registered clinical trials studies climbed from 399,499 in 2022 to 437,533 in 2023. Additionally, around 241,498 studies, or 53% of the total, were registered outside the United States, compared to 140,492 studies (31%) registered just in the United States. Therefore, the rising number of clinical trials is driving the growth of the antibody contract manufacturing market.
Technological advancements are a key trend gaining popularity in the antibody contract manufacturing market. Major companies operating in the antibody contract manufacturing market are adopting new technologies to sustain their position in the market. For instance, in October 2021, Merck KGaA, a Germany-based science and technology company, introduced ChetoSensar, an innovative technology aimed at addressing solubility challenges in antibody-drug conjugates (ADCs). Merck KGaA intends to leverage their expertise in contract development manufacturing for the development of next-generation antibody-drug conjugates and improve the effectiveness of high-potency active pharmaceutical ingredients (HPAPIs) by enhancing the solubility of these compounds through the innovative ChetoSensar technology.
The main products of antibody contract manufacturing are monoclonal antibodies, polyclonal antibodies, and others. Monoclonal antibodies (mAbs) are antibodies that are designed to target a specific antigen, and antibody contract manufacturing plays a significant role in producing monoclonal antibodies at a large scale, ensuring consistent quality and quantity for therapeutic or diagnostic applications. They are developed from sources such as mammals and microbes at preclinical, clinical, and commercial scales of operation that are used by end users such as biopharmaceutical companies, research laboratories, and others.
The antibody contract manufacturing market includes revenues earned by entities by providing services such as cell line development, process optimization, and the manufacturing of clinical trial materials. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Report Scope
Markets Covered:
- By Product: Monoclonal Antibodies; Polyclonal Antibodies; Other Products
- By Source: Mammalian; Microbial
- Scale Of Operation: Preclinical; Clinical; Commercial
- By End-User: Biopharmaceutical Companies; Research Laboratories; Other End Users
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Italy; Spain; Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Companies Profiled:
- AbbVie
- Thermo Fisher Scientific
- Boehringer Ingelheim Biopharmaceuticals
- Fujifilm Holdings
- Eurofins Scientific
- Lonza Group
- Labcorp Drug Development
- Catalent
- Charles River Laboratories International
- Merck
- Samsung Biologics
- Wuxi Biologics Cayman
- Pierre Fabre Group
- Siegfried Holding
- Recipharm
- Emergent BioSolutions
- Aenova Group
- Cambrex
- Aldevron LLC
- Novasep Holding SAS
- Synthon
- KBI Biopharma
- Nitto Avecia Pharma Services
- Cytovance Biologics
- AGC Biologics
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 175 |
| Forecast Period | 2023 - 2027 |
| Estimated Market Value (USD) in 2023 | $12.84 billion |
| Forecasted Market Value (USD) by 2027 | $21.79 billion |
| Compound Annual Growth Rate | 14.1% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/l6vnj1
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
